Markers for breast cancer

A method of determining the identity of the alleles of fewer than 1,000 single nucleotide polymorphisms (SNPs) in a woman subject selected from the group of subjects consisting of women in need of screening for breast cancer susceptibility to produce a polymorphic profile of the selected woman subject in need of breast cancer screening, comprising

• (i) obtaining a biological sample comprising a genome from the selected woman subject in need of breast cancer screening;
• (ii) selecting for allelic identity analysis at least a SNP located at rs2981582 within the nucleotide sequence of an intron of a Fibroblast Growth Factor Receptor 2 (FGFR2) gene, and a SNP located at rs13281615 within the genome of the selected woman subject in need of breast cancer screening;
• (iii) assaying, with a probe or a primer, whether
• a) the selected woman subject is homozygous or heterozygous for an adenine (A) or a guanine (G) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene in the biological sample of step (i),
• wherein
• if the assaying is with a primer, then the assaying comprises
• (1) hybridizing a primer to a nucleic acid having the sequence of a region proximal to the SNP located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene or
• (2) hybridizing a primer to a nucleic acid having the sequence of an allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene, and
• if the assaying is with a probe, then the assaying comprises
• (1) hybridizing a probe to a nucleic acid having the sequence of the adenine (A) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene and
• (2) hybridizing a probe to a nucleic acid having the sequence of the guanine (G) allele located at rs2981582 within the nucleotide sequence of the intron of the FGFR2 gene, and
• b) the selected woman subject is homozygous or heterozygous for an adenine (A) or a guanine (G) at the allele located at rs13281615 within the nucleotide sequence of the genome in the biological sample of step (i),
• wherein
• if the assaying is with a primer, then the assaying comprises
• (1) hybridizing a primer to a nucleic acid having the sequence of a region proximal to the SNP located at rs13281615 within the nucleotide sequence of the genome of the woman subject or
• (2) hybridizing a primer to a nucleic acid having the sequence of an allele located at rs13281615 within the nucleotide sequence of the genome of the woman subject, and
• if the assaying is with a probe, then the assaying comprises
• (1) hybridizing a probe to a nucleic acid having the sequence of the adenine (A) allele located at rs13281615 within the nucleotide sequence of the genome of the woman subject and
• (2) hybridizing a probe to a nucleic acid having the sequence of the guanine (G) allele located at rs13281615 within the nucleotide sequence of the genome of the woman subject, and
• (iv) producing the polymorphic profile of the selected woman subject in need of breast cancer screening based on the identity of the alleles assayed in step (iii),
• wherein fewer than 1,000 SNPs are selected for allelic identity analysis in step (ii) and the same fewer than 1,000 SNPs are assayed in step (iii).